AGAVE-201, A Phase 2, Open-label, Randomized, MulticenterStudy to Evaluate the Efficacy, Safety and Tolerability ofAxatilimab at 3 Different Doses in Patients with Recurrent orRefractory Active Chronic Graft Versus Host Disease who haveReceived at le

  • Arora, Mukta (PI)

Project: Research project

Project Details

Description

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at le
StatusActive
Effective start/end date11/1/2010/31/25

Funding

  • SYNDAX PHARMACEUTICALS

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.